Mol Psychiatry:APOE4+的非裔个体患AD的风险比欧裔个体低

2022-09-09 影像小生 MedSci原创

痴呆症在黑人中比在白人中更为普遍,这可能是由于环境和生物因素的共同作用。矛盾的是,临床研究表明非裔 (AFR) 的

痴呆症在黑人中比在白人中更为普遍,这可能是由于环境和生物因素的共同作用。矛盾的是,临床研究表明非裔 (AFR) 的APOE ε4 痴呆风险降低,但神经病理学数据的缺乏排除了对这些发现背后的生物学因素的解释,包括APOE ε4 风险与阿尔茨海默病 (AD)之间的关联病理学。

巴西圣保罗大学Michel Satya Naslavsky等调查了400名来自社区居住的混合巴西人的死后样本,研究非裔、AD相关神经病理学、APOE基因型和功能认知之间的相互作用,这些样本中有不同程度的AD病理严重程度,且缺乏共病神经病理学。研究结果发表在Mol Psychiatry。

表2. 临床痴呆评分方框总和(CDR-SOB)与非裔和AD神经病理负担的定量比例的关联(n = 400)。

1.非裔 (AFR) 比例的增加与神经炎性斑块 (NP) 的负担降低相关。

2.然而,对于有严重 NP 和神经原纤维缠结 (NFT) 负担的个体,AFR 比例与更差的临床痴呆评分框总和 (CDR-SOB) 相关。

图2. 通过神经病理学和APOE4状态分层的非裔与认知结果的关联

3.APOE ε4 携带者中,AFR 比例与 CDR-SOB 之间的关联消失了。

4.以相应的APOE4-作为参考,研究AD神经病理负担和功能认知评分与欧洲或非欧洲APOE4 +的相关性。

4.对 309 个人的子集的APOE本地血统推断表明,在APOE ε4 非携带者中,非欧裔APOE背景与较低的 NP 负担相关,并且在根据 NP 负担进行调整时,认知结果也比欧洲APOE更差。

5.仅在欧裔APOE背景下, APOE ε4 与更严重的 AD 神经病理学负担相关。

APOE基因型及其与 AD 神经病理学和临床模式的关联受血统的影响很大,与欧裔相比,AFR 与较低的 NP 负担和减弱的APOE ε 4风险相关。

总之,该研究证实了在AD研究中增加混合人群数量的必要性。提示神经病理学、临床结果和APOE基因分型因不同的祖先背景而不同。在APOE4 +中,AFR比例增加和功能认知评分下降之间的关联消失了,这支持了APOE4+的非裔个体患AD的风险比欧裔个体低的假设。

原文出乎

Naslavsky, M.S., Suemoto, C.K., Brito, L.A. et al. Global and local ancestry modulate APOE association with Alzheimer’s neuropathology and cognitive outcomes in an admixed sample. Mol Psychiatry (2022). https://doi.org/10.1038/s41380-022-01729-x

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2078473, encodeId=860120e8473c7, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Mon Jun 05 16:04:35 CST 2023, time=2023-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792338, encodeId=8a611e9233897, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Jul 02 21:04:35 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365731, encodeId=54ab1365e31c8, content=<a href='/topic/show?id=41ef26683f' target=_blank style='color:#2F92EE;'>#APOE4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2668, encryptionId=41ef26683f, topicName=APOE4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Sep 10 05:04:35 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590635, encodeId=cec3159063552, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Sat Sep 10 05:04:35 CST 2022, time=2022-09-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2078473, encodeId=860120e8473c7, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Mon Jun 05 16:04:35 CST 2023, time=2023-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792338, encodeId=8a611e9233897, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Jul 02 21:04:35 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365731, encodeId=54ab1365e31c8, content=<a href='/topic/show?id=41ef26683f' target=_blank style='color:#2F92EE;'>#APOE4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2668, encryptionId=41ef26683f, topicName=APOE4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Sep 10 05:04:35 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590635, encodeId=cec3159063552, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Sat Sep 10 05:04:35 CST 2022, time=2022-09-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2078473, encodeId=860120e8473c7, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Mon Jun 05 16:04:35 CST 2023, time=2023-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792338, encodeId=8a611e9233897, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Jul 02 21:04:35 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365731, encodeId=54ab1365e31c8, content=<a href='/topic/show?id=41ef26683f' target=_blank style='color:#2F92EE;'>#APOE4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2668, encryptionId=41ef26683f, topicName=APOE4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Sep 10 05:04:35 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590635, encodeId=cec3159063552, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Sat Sep 10 05:04:35 CST 2022, time=2022-09-10, status=1, ipAttribution=)]
    2022-09-10 bnjfy
  4. [GetPortalCommentsPageByObjectIdResponse(id=2078473, encodeId=860120e8473c7, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Mon Jun 05 16:04:35 CST 2023, time=2023-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792338, encodeId=8a611e9233897, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Jul 02 21:04:35 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365731, encodeId=54ab1365e31c8, content=<a href='/topic/show?id=41ef26683f' target=_blank style='color:#2F92EE;'>#APOE4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2668, encryptionId=41ef26683f, topicName=APOE4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Sep 10 05:04:35 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590635, encodeId=cec3159063552, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Sat Sep 10 05:04:35 CST 2022, time=2022-09-10, status=1, ipAttribution=)]
    2022-09-10 xiongke016

相关资讯

Alzheimer’s & Dementia:社会经济地位低的区域痴呆症漏诊率、延误诊断率高

在社会经济地位低的城市可能存在大量的痴呆症漏诊。

梅斯专栏:神经新前沿——AD前沿

整合神经科诊疗资讯

四川大学华西医院:痴呆及阿尔茨海默病进展要点简析

四川大学华西医院对痴呆及阿尔茨海默病的研究进展进行综述,旨在提升大众对痴呆的总体认识。

Neural Regeneration Research: dFCS可用于AD诊断、治疗和持续评估

动态连接强度的神经测量可能作为生物标志物,可用于AD的诊断、治疗和持续评估。

华西皮肤论坛丨AD诊疗路径中关键要点中国共识解读

在2022年第五届华西皮肤论坛上,来自四川大学华西医院的王婷婷教授做了题为《AD诊疗路径中关键要点中国共识解读》的报道。

华西皮肤论坛2022 丨冉玉平教授:审时“度”势——聚焦特应性皮炎长期管理

在2022第五届“华西皮肤论坛”会议上,四川大学华西医院皮肤性病科冉玉平教授以《审时“度”势-聚焦特应性皮炎长期管理》为题,对相关内容进行了详细的讲解。